Skip to main content
. 2023 Feb 19;10(12):2207499. doi: 10.1002/advs.202207499

Figure 4.

Figure 4

TIPE2 deficiency increases T‐bet and Eomes activity in NK cells. A) Percentages of T‐bet‐ or Eomes‐expressing cells among tumor‐infiltrating NK cells from MC38 tumor‐bearing Tipe2 WT/ WT mice or Tipe2 ΔNK/ΔNK mice 14 days post‐tumor challenge. B) MC38 tumor growth in WT, Tipe2 ΔNK/ΔNK, Tbx21 ΔNK/ΔNK, or Tipe2 ΔNK/ΔNK; Tbx21 ΔNK/ΔNK mice. C) MC38 tumor growth in WT, Tipe2 ΔNK/ΔNK, Eomes ΔNK/ΔNK, or Tipe2 ΔNK/ΔNK; Eomes ΔNK/ΔNK mice. D) Percentages of perforin‐expressing cells among tumor‐infiltrating NK cells from MC38‐bearing Tipe2 WT/ WT, Tipe2 ΔNK/ΔNK, Tipe2 ΔNK/ΔNK; Tbx21 ΔNK/ΔNK, or Tipe2 ΔNK/ΔNK; Eomes ΔNK/ΔNK mice 29 days post‐tumor challenge. E) MC38 tumor growth in WT, Tipe2 ΔNK/ΔNK, Prf1 ΔNK/ΔNK, or Tipe2 ΔNK/ΔNK; Prf1 ΔNK/ΔNK mice. F) Numbers of tumor‐infiltrating CD8+ T cells per gram of tumor tissue and percentages of IFN‐γ‐producing cells among tumor‐infiltrating CD8+ T cells upon PMA and Ionomycin stimulation ex vivo in MC38 tumor‐bearing WT, Tipe2 ΔNK/ΔNK, Prf1 ΔNK/ΔNK, or Tipe2 ΔNK/ΔNK; Prf1 ΔNK/ΔNK mice 28 days post‐tumor challenge. A–F) Data are mean values ± SEM representative of two independent experiments (n = 6). *p < 0.05, **p < 0.005, ***p < 0.001 (two‐tailed Student's t‐test for (A, D, F); two‐way ANOVA for (B, C, E)).